RESEARCH OF EFFECTIVENESS OF MULTIFUNCTION
PEPTIDE SUPPLEMENT REVILAB ML 03
Study period — april 2017 – August 2019
Location — Russia, Moscow, Moscow office of the Peptides
Research and Production Center of Revitalization and Health
Actual enrolment — 80 participants
Age — 42–54 y.o.
Dosage regimen — 1 capsule in the morning a.c. daily
Period of administration — 4 months
EFFECTIVENESS OF REVILAB ML 03
Parameter Placebo Placebo group ML 03 group ML 03 group
group before after research, before research, after research,
research,
42 patients 42 patients 38 patients 38 patients
Unstable blood 34 (81%) 28 (67%) 31 (82%) 12* (32%)
tension
Sleep onset 38 (90%) 30 (71%) 34 (89%) 14* (37%)
disorder
Rapid fatigability 42 (100%) 36 (86%) 38 (100%) 9* (24%)
Headache 26 (62%) 24 (57%) 29 (76%) 12* (32%)
Vision impairment 31 (74%) 29 (69%) 32 (84%) 13* (34%)
(blurred vision in
the evening)
* Accurate changes in comparison with the placebo group.
90 // Health territory. PEPTIDES. Memory, intelligence and vision
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.